228 related articles for article (PubMed ID: 3141084)
1. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
Niwa T; Takeda N; Tatematsu A; Maeda K
Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
[TBL] [Abstract][Full Text] [Related]
3. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats.
Niwa T; Yazawa T; Ise M; Sugano M; Kodama T; Uehara Y; Maeda K
Nephron; 1991; 57(1):84-8. PubMed ID: 1904558
[TBL] [Abstract][Full Text] [Related]
5. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
[TBL] [Abstract][Full Text] [Related]
6. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
Mabuchi H; Nakahashi H
Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
[TBL] [Abstract][Full Text] [Related]
7. Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
Oda A; Suzuki Y; Sato B; Sato H; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
J Sep Sci; 2022 May; 45(10):1672-1682. PubMed ID: 35247297
[TBL] [Abstract][Full Text] [Related]
8. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
[TBL] [Abstract][Full Text] [Related]
9. Indoxyl-beta-D-glucuronide and 3-indoxyl sulfate in plasma of hemodialysis patients.
Agatsuma S; Sekino H; Watanabe H
Clin Nephrol; 1996 Apr; 45(4):250-6. PubMed ID: 8861801
[TBL] [Abstract][Full Text] [Related]
10. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.
Niwa T; Yazawa T; Kodama T; Uehara Y; Maeda K; Yamada K
Nephron; 1990; 56(3):241-5. PubMed ID: 2077405
[TBL] [Abstract][Full Text] [Related]
11. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.
Taki K; Tsuruta Y; Niwa T
Am J Nephrol; 2007; 27(1):30-5. PubMed ID: 17215572
[TBL] [Abstract][Full Text] [Related]
12. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R
PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of indoxyl-beta-D-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis.
Niwa T; Miyazaki T; Tsukushi S; Maeda K; Tsubakihara Y; Owada A; Shiigai T
Nephron; 1996; 74(1):72-8. PubMed ID: 8883023
[TBL] [Abstract][Full Text] [Related]
14. Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography.
Stanfel LA; Gulyassy PF; Jarrard EA
Clin Chem; 1986 Jun; 32(6):938-42. PubMed ID: 3085981
[TBL] [Abstract][Full Text] [Related]
15. Protein-bound uremic retention solutes.
Brunet P; Dou L; Cerini C; Berland Y
Adv Ren Replace Ther; 2003 Oct; 10(4):310-20. PubMed ID: 14681860
[TBL] [Abstract][Full Text] [Related]
16. Rapid assay for indoxyl sulphate in uremic serum by internal-surface reversed-phase high-performance liquid chromatography.
Takeda N; Niwa T; Maeda K; Shibata M; Tatematsu A
J Chromatogr; 1988 Oct; 431(2):418-23. PubMed ID: 3149642
[No Abstract] [Full Text] [Related]
17. Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease.
Jhawar S; Singh P; Torres D; Ramirez-Valle F; Kassem H; Banerjee T; Dolgalev I; Heguy A; Zavadil J; Lowenstein J
PLoS One; 2015; 10(3):e0118703. PubMed ID: 25811877
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Indoxyl Sulfate Dialyzer Clearance with the Use of Binding Competitors.
Tao X; Thijssen S; Levin N; Kotanko P; Handelman G
Blood Purif; 2015; 39(4):323-30. PubMed ID: 25998324
[TBL] [Abstract][Full Text] [Related]
19. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
[TBL] [Abstract][Full Text] [Related]
20. Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography.
de Loor H; Meijers BK; Meyer TW; Bammens B; Verbeke K; Dehaen W; Evenepoel P
J Chromatogr A; 2009 May; 1216(22):4684-8. PubMed ID: 19394619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
